Show simple item record

dc.contributor.authorHouda, I
dc.contributor.authorDickhoff, C
dc.contributor.authorUyl-de Groot, CA
dc.contributor.authorReguart, N
dc.contributor.authorProvencio, M
dc.contributor.authorLevy, A
dc.contributor.authorDziadziuszko, R
dc.contributor.authorPompili, C
dc.contributor.authorDi Maio, M
dc.contributor.authorThomas, M
dc.contributor.authorBrunelli, A
dc.contributor.authorPopat, S
dc.contributor.authorSenan, S
dc.contributor.authorBahce, I
dc.coverage.spatialEngland
dc.date.accessioned2024-05-29T13:28:47Z
dc.date.available2024-05-29T13:28:47Z
dc.date.issued2024-03-01
dc.identifierARTN 100839
dc.identifierS2666-7762(24)00006-1
dc.identifier.citationThe Lancet Regional Health - Europe, 2024, 38 pp. 100840 -en_US
dc.identifier.issn2666-7762
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6257
dc.identifier.eissn2666-7762
dc.identifier.eissn2666-7762
dc.identifier.doi10.1016/j.lanepe.2024.100840
dc.identifier.doi10.1016/j.lanepe.2024.100840
dc.description.abstractThe treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments often differ between European countries, access to emerging developments may lead to inequalities due to variations in recommended and available lung cancer care throughout Europe. This Series paper (i) highlights the clinical studies reshaping the treatment landscape in resectable early-stage NSCLC, (ii) compares and contrasts approaches taken by the European Medicines Agency (EMA) for drug approval to that taken by the United States Food and Drug Administration (FDA), and (iii) evaluates the differences in access to emerging treatments from an availability perspective across European countries.
dc.formatElectronic-eCollection
dc.format.extent100840 -
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofThe Lancet Regional Health - Europe
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectAccess to primary care
dc.subjectAdjuvant chemotherapy
dc.subjectBiomarkers
dc.subjectDisease-free survival
dc.subjectEurope
dc.subjectHumans
dc.subjectImmune checkpoint inhibitors
dc.subjectLung neoplasms
dc.subjectNon-small-cell lung cancer
dc.subjectProtein kinase inhibitors
dc.subjectSurgery
dc.subjectUnited States
dc.subjectUnited States Food and Drug Administration
dc.titleNew systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-01-08
dc.date.updated2024-05-29T13:28:24Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.lanepe.2024.100840en_US
rioxxterms.licenseref.startdate2024-03-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38476748
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.lanepe.2024.100840
pubs.volume38
dc.contributor.icrauthorPopat, Sanjay
icr.provenanceDeposited by Mr Arek Surman on 2024-05-29. Deposit type is initial. No. of files: 1. Files: New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/